{
    "2020-06-08": [
        [
            {
                "time": "",
                "original_text": "研发投入约1100万，华东医药子公司多潘立酮片通过一致性评价！",
                "features": {
                    "keywords": [
                        "研发投入",
                        "华东医药",
                        "多潘立酮片",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业2020年6月投资月报：医药的牛市 是从什么时候开始的？",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资月报",
                        "牛市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "华东医药(000963.SZ)：多潘立酮片国内前三家通过一致性评价",
                "features": {
                    "keywords": [
                        "华东医药",
                        "多潘立酮片",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "华东医药：多潘立酮片通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "华东医药",
                        "多潘立酮片",
                        "仿制药",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【兴证医药】CXO（创新药产业链）的过去、现在和未来----医药行业周报",
                "features": {
                    "keywords": [
                        "兴证医药",
                        "CXO",
                        "创新药产业链",
                        "医药行业周报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}